Kausik Ray

Professor, EAS President

Professor Kausik Ray, BSc(Hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA

Kausik Ray is a Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Disease Prevention and the Deputy Director of the Imperial Clinical Trial Unit, Imperial College London, and a Consultant Cardiologist.

Contributions

NLA/EAS joint session - Primordial prevention: The neglected topic - Discussion and Q&ANLA/EAS joint session - Primordial prevention: The neglected topic90th EAS Congress 2022WHF Session 2: Global FH - Panel discussionFH Week 202290th EAS Congress 2022WHF Session 2: Global FH(DyslipidemiaMonogenicFHheLipidologyHypercholesterolemiaPrimary HyperlipidemiaReview)Why and how to implement early combination lipid lowering therapy - Discussion and Q&A90th EAS Congress 2022Why and how to implement early combination lipid lowering therapyAn App to guide clinical care - what is it and how should we use it90th EAS Congress 2022Why and how to implement early combination lipid lowering therapyObicetrapib lowers LDL-C in patients on high intensity statins results from the rose trial (nct04753606)90th EAS Congress 2022Late breaker session 1WHF Session 1: WHF Roadmap on Cholesterol update - Discussion and Q&A90th EAS Congress 2022WHF Session 1: WHF Roadmap on Cholesterol updateOverall Concept90th EAS Congress 2022WHF Session 1: WHF Roadmap on Cholesterol updateReimagining population health-the time is now - Discussion and Q&AReimagining population health-the time is now90th EAS Congress 2022Reimagining prevention: the population approachReimagining population health-the time is now90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now? - Discussion and Q&A90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?What’s been achieved and what more is needed - real world evidence90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention - Discussion and Q&A90th EAS Congress 2022Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD PreventionThe epidemiology of DM and obesity and risk of ASCVD90th EAS Congress 2022Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD PreventionThe role of new lipid lowering drugsEAS AC on FHThe population burden of FH- The need to close the gapEAS AC on FHHDL, non HDL cholesterol and TG - a role in atherosclerosis?EAS AC in LipidologyFamilial hypercholesterolemia detection and treatment and the EAS InitiativesEAS AC in LipidologyWhat do we know so far about bempedoic acid?88th EAS Congress 2020siRNA based approaches targeting hepatic synthesis of PCSK988th EAS Congress 2020Risk Prediction for Add on Lipid Modulating Therapy87th EAS Congress 2019Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? - Introduction85th EAS Congress 2017Familial hypercholesterolaemia85th EAS Congress 2017Cardiovascular risk assessment and lipid lowering for patients with DM - what do the guidelines say?2019 ESC-EAS Dyslipidaemia Guidelines

Report

Contains abusive or derogatory content
Contains mature or sensitive content
Contains misleading or false information
Contains spam, fake content or potential malware
Harassment or bullying behavior

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .